Loading…
Guangxi TCM maker best known for Xiguashuang (watermelon frost) throat and mouth-ulcer remedies sold nationwide.
Guangxi TCM maker best known for Xiguashuang (watermelon frost) throat and mouth-ulcer remedies sold nationwide.
Earns mostly from a few long-established over-the-counter products, led by Watermelon Frost, sold through distributors to pharmacies, so one brand carries the company. Because these are self-medication products, demand depends on brand recognition and pharmacy shelf space, not doctors' prescriptions.
In one line: A Chinese TCM throat-lozenge maker (like a herbal Chloraseptic).
Moat: narrow (brand). Well-known heritage OTC brand for throat ailments with wide pharmacy distribution.
Headquarters: Guilin, Guangxi, China · Employees: 2,563
Size Guilin Sanjin Pharmaceutical (002275.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.53B, the 1607th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥18.20 on 6 Nov 2026.
Performance Over six months the shares gained 27.2%, against -8.3% for the median peer and -16.4% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 2.6% over the last twelve months (peer median +9.6%); the operating margin is 24.4% (peer median 14.8%).
Valuation It trades at 18.6× forward earnings against a peer median of 15.7× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 15.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.03B | CN¥2.03B | CN¥2.17B | CN¥2.15B | CN¥1.94B |
| Revenue growth | — | -7% | +1% | +11% | — |
| Gross profit | CN¥1.60B | CN¥1.49B | CN¥1.55B | CN¥1.51B | CN¥1.32B |
| EBITDA | n/a | CN¥616M | CN¥607M | CN¥585M | CN¥440M |
| Net income | CN¥422M | CN¥433M | CN¥522M | CN¥421M | CN¥330M |
| Free cash flow | CN¥630M | CN¥633M | CN¥515M | CN¥479M | CN¥473M |
| Capital expenditure | CN¥94.6M | CN¥123M | CN¥82.2M | CN¥76.4M | CN¥62.3M |
| Total debt | CN¥356M | CN¥514M | CN¥594M | CN¥530M | CN¥466M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guilin Sanjin Pharmaceutical 002275.SZ | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002275.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +49.3% | -0.2% | highest of 21 |
| 6-month return | +27.2% | -8.3% | 6th highest of 21 |
| Distance from 52-week high | -5.8% | -23.1% | 3rd highest of 21 |
| Revenue growth (TTM) | -2.6% | +9.6% | 6th lowest of 21 |
| Operating margin | 24.4% | 14.8% | 5th highest of 20 |
| Forward P/E | 18.6× | 15.7× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -2.2% | 1.5% | 5th least demanding of 17 |
| Growth delivered (Del g) | +5.5% | +10.5% | 6th lowest of 17 |
| Hurdle (Req g minus delivered) | -7.7 pp | -9.9 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | +15.1 pp | +2.7 pp | 4th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% | +7.1% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% | +5.3% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |